Metabolic syndrome is related to multiple cardiovascular risk factors. Visceral adipose tissue (VAT) plays a key role in metabolic syndrome. Easy detection of VAT could be an important tool to increase knowledge of metabolic syndrome. The objective of this study was to study the relationship of echocardiographic epicardial adipose tissue to anthropometric and clinical parameters of metabolic syndrome. We selected 72 consecutive subjects, 46.5 ؎ 17. M ETABOLIC SYNDROME IS related to multiple cardiovascular risk factors (1-3). There are no wellaccepted criteria for the diagnosis of metabolic syndrome. Nevertheless, it is identified by the presence of three or more metabolic alterations, such as abdominal obesity, hypertension, impaired fasting glucose or glucose intolerance, high levels of triglycerides, low levels of high-density lipoprotein cholesterol, and insulin resistance (4). Plasma adiponectin and C-reactive protein (CRP) have also been proposed to be related to central adiposity and cardiovascular risk (5-7).Visceral obesity seems to play a key role in the development of all features of metabolic syndrome (8 -15). Hence, detection of visceral adipose tissue (VAT), the fat deposited around the internal organs, might be important for risk stratification of metabolic syndrome. Nevertheless, it is difficult to obtain an accurate measurement and characterization of VAT. Several methods are applied as surrogates for estimation of VAT. Anthropometric measurements are the most used, but are frequently imprecise. However, waist circumference is widely accepted as a good predictor of intraabdominal fat mass (16, 17). Imaging techniques are certainly more precise and reliable than anthropometric measurements. Magnetic resonance imaging (MRI), the gold standard technique, estimates VAT accurately, but unfortunately it is costly (18). Recently, we have proposed and validated a new method to estimate VAT by echocardiographic epicardial adipose tissue measurement (19). Epicardial adipose tissue is a true visceral fat deposited around the heart with characteristics of a high insulin-resistant tissue. Epicardial adipose tissue measurement could be an important tool to increase knowledge of metabolic syndrome on epidemiological basis.The aim of this work was to study the relationship of echocardiographic epicardial adipose tissue to anthropometric, metabolic, and cardiac parameters of metabolic syndrome. Subjects and Methods SubjectsWe selected 72 consecutive subjects (Caucasian; 36 females and 36 males), 46.5 Ϯ 17.4 yr of age, with a body mass index (BMI) between 22 and 47 kg/m 2 (median, 34). Echocardiographic measurements were performed in all subjects during routine examinations. Metabolic syndrome was identified by the presence of three or more of the following parameters: BMI greater than 30 kg/m 2 , predominant truncal/abdominal fat distribution (value of waist circumference Ͼ88 cm in women and Ͼ102 cm in men), impaired fasting glucose (fasting glucose Ͼ110 mg/ dl), hypertension (systolic arterial blood pressure Ͼ13...

This is the first study demonstrating that children with CD may have patchy villous atrophy of the duodenum. The bulb mucosa may be the only duodenal area involved, both at diagnosis and after gluten challenge. Therefore, multiple endoscopic biopsies should always be performed, not only in the distal duodenum, but also in the bulb.

BackgroundNon-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder worldwide, reaching prevalence up to 90 % in obese patients with type 2 diabetes (T2D), and representing an independent risk factor for cardiovascular mortality. Furthermore, the coexistence of T2D and NAFLD leads to higher incidence of diabetes’ complications and additive detrimental liver outcomes. The existence of a close association between NAFLD and hypovitaminosis D, along with the anti-inflammatory and insulin-sensitizing properties of vitamin D, have been largely described, but vitamin D effects on hepatic fat content have never been tested in a randomized controlled trial. We assessed the efficacy and safety of 24-week oral high-dose vitamin D supplementation in T2D patients with NAFLD.MethodsThis randomized, double-blind, placebo-controlled trial was carried out at the Diabetes Centre of Sapienza University, Rome, Italy, to assess oral treatment with cholecalciferol (2000 IU/day) or placebo in T2D patients with NAFLD. The primary endpoint was reduction of hepatic fat fraction (HFF) measured by magnetic resonance; as hepatic outcomes, we also investigated changes in serum transaminases, CK18-M30, N-terminal Procollagen III Propeptide (P3NP) levels, and Fatty Liver Index (FLI). Secondary endpoints were improvement in metabolic (fasting glycaemia, HbA1c, lipids, HOMA-IR, HOMA-β, ADIPO-IR, body fat distribution) and cardiovascular (ankle-brachial index, intima-media thickness, flow-mediated dilatation) parameters from baseline to end of treatment.ResultsSixty-five patients were randomized, 26 (cholecalciferol) and 29 (placebo) subjects completed the study. 25(OH) vitamin D significantly increased in the active treated group (48.15 ± 23.7 to 89.80 ± 23.6 nmol/L, P < 0.001); however, no group differences were found in HFF, transaminases, CK18-M30, P3NP levels or FLI after 24 weeks. Vitamin D neither changed the metabolic profile nor the cardiovascular parameters.ConclusionsOral high-dose vitamin D supplementation over 24 weeks did not improve hepatic steatosis or metabolic/cardiovascular parameters in T2D patients with NAFLD. Studies with a longer intervention period are warranted for exploring the effect of long time exposure to vitamin D.Trial registrationThis trial was approved on July 2011 by the Ethics Committee of Policlinico Umberto I, Sapienza University of Rome, Italy, and registered at www.clinicaltrialsregister.eu number 2011-003010-17.Electronic supplementary materialThe online version of this article (doi:10.1186/s12916-016-0638-y) contains supplementary material, which is available to authorized users.

OBJECTIVEZinc transporter 8 (ZnT8) is an islet β-cell secretory granule membrane protein recently identified as an autoantibody antigen in type 1 diabetes. The aim of this study was to determine the prevalence and role of antibodies to ZnT8 (ZnT8As) in adult-onset diabetes.RESEARCH DESIGN AND METHODSZnT8As were measured by a radioimmunoprecipitation assay using recombinant ZnT8 COOH-terminal or NH2-terminal proteins in 193 patients with adult-onset autoimmune diabetes having antibodies to either GAD (GADAs) or IA-2 (IA-2As) and in 1,056 antibody-negative patients with type 2 diabetes from the Non Insulin Requiring Autoimmune Diabetes (NIRAD) study.RESULTSZnT8As-COOH were detected in 18.6% patients with autoimmune diabetes and 1.4% with type 2 diabetes. ZnT8As-NH2 were rare. ZnT8As were associated with younger age and a high GADA titer. The use of GADAs, IA-2As, and ZnT8As in combination allowed a stratification of clinical phenotype, with younger age of onset of diabetes and characteristics of more severe insulin deficiency (higher fasting glucose and A1C, lower BMI, total cholesterol, and triglycerides) in patients with all three markers, with progressive attenuation in patients with two, one, and no antibodies (all Ptrend < 0.001). Autoantibody titers, association with high-risk HLA genotypes, and prevalence of thyroid peroxidase antibodies followed the same trend (all P < 0.001).CONCLUSIONSZnT8As are detectable in a proportion of patients with adult-onset autoimmune diabetes and seem to be a valuable marker to differentiate clinical phenotypes.